deletion or TP53 mutation who are unsuitable for chemo-immunotherapy. Ibrutinib is being co-developed by Johnson & Johnson ( JNJ -0.2% ) unit Janssen-Cilag International NV and Pharmacyclics Switzerland GmbH. Once approved, Janssen
LONDON, July 25 (Reuters) - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a...
Balanced Investing : Bringing Sandra Peterson to turnaround the failing McNeil Consumer Healthcare division of Johnson & Johnson ( NYSE : JNJ ) has proven quite fruitful for the company. Although her strategic moves may have sounded abrupt at the beginning
Organovo (NYSEMKT: ONVO ) are up 17% premarket on robust volume in response the signing of a research agreement with Johnson & Johnson unit Janssen Research and Development to evaluate the use of 3D bio-printed tissue in drug discovery. Financial
in our valuation. With quarterly revenue growth of 1% in constant currency, Zimmer trailed rivals Stryker and Johnson & Johnson 's DePuy business. In recent quarters, Zimmer has benefited from the introduction of its new Persona knee. However
Balanced funds thread examined income builder funds and specifically Thornburg Income Builder. I'll let that rest. I sold JNJ recently when it topped 100 - had a great gain - love the company and the industry - but don't like the ~2.7 yield
a Phase 3 trial comparing a once-daily dose of Solzentry ( maraviroc ) ( PFE +0.7% ) with Prezista (darunavir) ( JNJ +1.1% ) and Norvir (ritonavir) ( ABBV +0.2% ) to emtricitabine / tenofir with darunavir plus ritonavir (DRV
By Andrew Stephan : Although a very small company by Wall Street standards, Bovie Medical Corporation (NYSEMKT: BVX ) has been developing very promising new medical device technologies that could have major impacts on some important areas in the healthcare industry, such as surgery and wound care.
The BOD of J & J ( JNJ -0.5% ) authorizes the repurchase of up to $5B of the company's common stock. Shares will be bought at management's discretion
By Stock Doctor : Investors in biotechnology stocks, including myself, are always trying to balance risk and reward when purchasing stocks in this highly volatile sector. Having a biomedical Ph.D., I spend endless hours poring over data looking for underappreciated stocks with significant upside ...